Kornimate/medical-research-clean huggingface dataset:
delivered dietary intervention for children with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome; Abdominal Pain

Summary: the purpose of this study is to determine whether a specific diet may help children with irritable bowel syndrome.

many children experience stomach pain or discomfort at some point during their lives. some children have belly discomfort frequently while others rarely have this problem. there have been very few studies to test treatments for recurrent stomach discomfort in children. recently, studies in adults with recurrent stomach discomfort suggest that diet changes may help. currently, we do not know if these same diets will work in children with the same problem. in this study, two different diets will be provided (delivered) for two days with at least 5 days in between each provided diet. the child's symptoms will be recorded over the two days of each diet. children will be asked to capture samples of their breath during the last day of the each two day delivered diet. stool samples will also be collected.

Eligibility criteria:
inclusion criteria: must include all of the following: 1. children between the ages of 7-17 years; 2. meet the criteria for ibs based on the questionnaire on pediatric gastrointestinal symptoms rome iii version, including pain/discomfort a minimum of twice per week; 3. negative physician evaluation for an organic etiology of the pain within the past year exclusion criteria: will include any of the following: 1. diabetes or other disease process requiring specialized dietary management; 2. malnutrition or obesity (bmi \>95%); 3. inability to eat by mouth; 4. antibiotic or medicinal probiotic usage within the past 3 months (excluding yogurt); 5. neuromodulator (e.g. amitriptyline) usage within the past 3 months 6. start of, or change in gastrointestinal medication (e.g. laxative) dose that may cause or ameliorate abdominal symptoms within the past month

Keywords: irritable bowel syndrome children chronic abdominal pain recurrent abdominal pain
cyclin dependent kinase (cdk)4/6 inhibitor, pd0332991 in advanced non-small cell lung cancer nsclc.

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to determine the efficacy and the toxicities of the study drug pd0332991 in the treatment of patients with stage iv non-small cell lung cancer with wildtype retinoblastoma protein (rb) and inactivated cyclin dependent kinase (cdk) n2a in the tumor.

the oral drug pd0332991 is a highly selective reversible inhibitor of cyclin-dependent kinases 4 \& 6 that is being studied for use in the treatment of advanced non-small cell lung cancer.

Eligibility criteria:
inclusion criteria: * histologically or cytologically proven non small cell lung cancer * stage iv (m1a or m1b) disease. patients may also have recurrence of early-stage disease or locally advanced disease with the presence of new distant metastases. * cyclin dependent kinase (cdk)n2a (p16) protein absent or expressed at a low level in tumor biopsy specimen * failed or intolerant of at least one prior systemic chemotherapy regimen (there is no maximum number of prior chemotherapy regimens) * eastern cooperative oncology group (ecog) performance status 0-2 * age \>18 years. * adequate organ and bone marrow function * measurable disease by standard recist v1.1 criteria * life expectancy of greater than 3 months exclusion criteria: * inability to understand or sign the informed consent document * inability or unwillingness to take oral medications * no available tissue specimen for p16 analysis * chemotherapy or radiotherapy within 3 weeks prior to beginning the study drug * other investigational agents within 4 weeks prior to beginning the study drug * all side effects from previous chemotherapy, radiotherapy or investigational agents not resolved, returned to baseline or returned to grade 1 toxicity (exceptions are grade 2 alopecia and grade 2 peripheral neuropathy) * major surgery within 4 weeks prior to beginning the study drug * surgical scar from previous surgery not healed prior to beginning the study drug * high-dose or chronic steroid use * high-dose statins within 7 days * history of rhabdomyolysis * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, stroke or myocardial infarction within 3 months, or psychiatric illness/social situations that would limit compliance with study requirements. * baseline corrected qt interval (qtc) \>470ms * pre-existing clinically significant cardiac, hepatic or renal dysfunction at the discretion of the treating physician * untreated or uncontrolled (symptomatic or asymptomatic) brain metastases * leptomeningeal carcinomatosis * inability or unwillingness to use contraception during the treatment period by patients with reproductive potential. * pregnant or breastfeeding women * hiv-positive patients on combination antiretroviral therapy

Keywords: advanced stage
high altitude residents with high altitude pulmonary hypertension (haph), sdb assessed at ha (3200 m) vs la (760 m)

Conditions: High Altitude Pulmonary Hypertension

Summary: to study the effect of relocation from 3200m (aksay) to 760m (bishkek) in highlanders with high altitude pulmonary hypertension (haph) who permanently live \>2500m on sleep disordered breathing

this research in highlanders with haph diagnosed by echocardiography and defined by a rv/ra \>30 mmhg who permanently live at ha \>2500 m will have nocturnal respiratory sleep studies near their living altitude in aksay at 3200 m and on night 1 and 6 at 760m after relocation.

Eligibility criteria:
inclusion criteria: * permanently living \>2500 m * haph diagnosed with a minimum rv/ra of 30 mmhg assessed by echocardiography at an altitude of 3200 m * written informed consent exclusion criteria: * highlanders who cannot follow the study investigations, * patients with moderate to severe concomitant lung disease (fev1\ 20 cigarettes/day or \>20 pack-years. * coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months * regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Keywords: pulmonary hypertension hypoxia high altitude sleep disordered breathing
assessment of skeletal maturity using proximal femoral epiphysis in patients with scoliosis

Conditions: Idiopathic Scoliosis

Summary: this study aims to explore the use of proximal femoral head for the assessment of skeletal maturity in patients with idiopathic scoliosis. the aim is to validate the use of the stages of proximal femoral epiphyseal closure in assessing pubertal growth landmarks in this patient cohort. the grading system of this skeletal maturity index will be established and its reliability and reproducibility in clinical use will be examined.

there are multiple skeletal maturity measures currently in use which were established with reliability in assessing growth. the advantages and shortcomings of each index was previously examined. this study aims to explore the use of proximal femoral epiphysis, which is in close proximity of the radiographic field of the spine, in assessing the growth status of patients with idiopathic scoliosis. the stages of the proximal femoral epiphyseal ossification has been established with specific definitions. the reliability and reproducibility of using these gradings will be examined by orthopaedic surgeons. subsequently, the assessment of different pubertal growth landmarks using these gradings will be validated, and to see whether these gradings can provide indications of peak growth and growth cessation. finally, the relationships of such growth assessment using this proximal femoral epiphysis ossification (pfeo) system and the curve progression in idiopathic scoliosis will be studied.

Eligibility criteria:
inclusion criteria: * idiopathic scoliosis * open triradiate cartilage or open distal radius epiphysis without capping exclusion criteria: * non-idiopathic scoliosis * patients with growth hormone deficiency or developmental delay * patient has not reached skeletal maturity * defaulted and lost to follow-up
brief stresses experimental study

Conditions: DNA Damage; Psychological Stress

Summary: the goal of this study is to examine the impact of psychological stress on dna integrity by conducting an experiment under controlled conditions with healthy volunteers to directly test the extent to which acute stress increases dna damage, while simultaneously testing the blocking effects of pre-treatment with propranolol, and exploring key hypothesized mediators and moderators of the severity of the dna damage.


Eligibility criteria:
inclusion criteria: * age 20-59 * weigh at least 110 pounds * fasting blood sugar below 150 mg/dl, or random blood sugar below 200 mg/dl * thyroid stimulating hormone level between 0.25 mu/l and 6.0 mu/l * resting blood pressure below 160/100 mm hg * if female, have either regular menstrual periods (21-35 days) or are post-menopausal exclusion criteria: * use of illicit drugs or nicotine-containing products other than cigarettes in the past month * current alcohol abuse * diagnosed with any of the following: cancer (other than basal cell skin cancer), chronic obstructive pulmonary disorder (copd), multiple sclerosis (ms), severe traumatic brain injury, hypertension (high blood pressure), coronary artery disease, congestive heart failure, or other serious heart disease * current diabetes, asthma, depression, bipolar disorder, anxiety, or schizophrenia * if female, pregnancy or breastfeeding within the past 3 months * if female, taking any medications that prevent monthly menstrual cycles (e.g., birth control shot, iud, "seasonal" birth control) * resting systolic blood pressure of \< 90 mm hg or resting pulse \< 50 beats per minute
a modified (retro-tubercle) opening wedge high tibial osteotomy versus the conventional technique

Conditions: Genu Varum

Summary: the present study was conducted among a group of iranian patients suffering from varus knee in order to compare advantages and disadvantages of rowhto (retro-tubercle opening wedge high tibial osteotomy) technique when compared with previously described approaches of opening-wedge osteotomy.

there are various methods for correcting varus deformity; therefore the best surgical method must be individualized. we concluded that in a varus knee where only correction in the coronal plane without patella infra, changes in q- angle, tibial plateau inclination is all that is needed, a retro- tubercle medial opening- wedge osteotomy is the preferred approach.

Eligibility criteria:
inclusion criteria: * symptomatic varus deformity of the knee with 2 or more degrees of anatomical axis varus without ligament injury exclusion criteria: * fractures through compartments of the knee or the patella * osteoarthritis other than in the medial compartment * 10 degrees or more extension lag * tibial malrotation
levonorgestrel-releasing intrauterine system (lng-ius) in the management of atypical endometrial hyperplasia

Conditions: Endometrial Hyperplasia

Summary: the purpose of this research study is to compare the uterus tissue of women who receive an intrauterine system to treat their endometrial hyperplasia with the uterine tissue of women who receive megestrol acetate to treat their hyperplasia. while both methods are commonly used in practice, investigators would like to see what effects each treatment has on uterine tissue.

primary objective: to determine if levonorgestrel-releasing intrauterine system is of equal efficacy to the standard systemic progestin therapy (megestrol acetate) based on endometrial sampling at 6 months after randomization. non-inferiority analysis. secondary objective(s): * to determine the safety of each treatment modality. * determine the feasibility of transvaginal ultrasound to predict treatment response.

Eligibility criteria:
inclusion criteria: * complex atypical endometrial hyperplasia only. confirmed by pathology report. * normal renal function and liver function tests. * age 18 or older. * the effects of megestrol acetate on the developing human fetus at the recommended therapeutic dose are unknown. for this reason and because megestrol acetate is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. exclusion criteria: * prior complex atypical endometrial hyperplasia or carcinoma. * prior hormone sensitive malignancy.\] * exogenous estrogen or progestin use presently or within the past 12 months. * standard contraindications to progestin therapy. * standard contraindications to intrauterine device use. * simple hyperplasia, complex hyperplasia without atypia (may be present in addition to atypical endometrial hyperplasia). * endometrial carcinoma (worrisome or possible carcinoma not exclusionary but requires dilatation and curettage if based only on office biopsy). * pregnant women are excluded from this study because megestrol acetate has the potential for teratogenic or abortifacient effects. because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with megestrol acetate, breastfeeding should be discontinued if the mother is treated with megestrol acetate.
intracorporeal anastomosis versus extracorporeal anastomosis for left colon cancer

Conditions: Colon Cancer

Summary: this study aims to investigate the effects of intracorporeal anastomosis and extracorporeal anastomosis in laparoscopic-assisted radical left hemicolectomy on surgical site infection. also consider perioperative recovery, safety, and oncology outcomes.

this is a prospective, randomized controlled trial. in this trial, cases in the intracorporeal anastomosis group and the extracorporeal anastomosis group are allocated at a 1:1 ratio among patients undergoing laparoscopic radical left hemicolectomy. the peri-operative recovery data, complications, oncology outcomes, and survival are compared.

Eligibility criteria:
inclusion criteria 1. age between 18 and 80 years; 2. histologically or cytologically confirmed left-sided colon cancer (distal transverse colon, left colic flexure, descending colon, or proximal sigmoid colon); 3. clinical stage t1-4a, n0-2, and m0; 4. eastern cooperative oncology group (ecog) performance status ≤ 2; 5. suitable for laparoscopic colectomy; 6. no previous systemic chemotherapy or radiotherapy; 7. willing to provide written informed consent and comply with the research procedures. exclusion criteria 1. have a history of malignant colorectal tumor or have metastatic or multiple carcinoma. 2. patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. who need emergency surgery. 3. patients who need to undergo combined organ resection or robot-assisted colectomy. 4. patients who are receiving preoperative neoadjuvant therapy. 5. asa grade ≥ iv and/or ecog performance status score \> 2. 6. cardiopulmonary dysfunction (nyha cardiac function classification ii-iv), liver dysfunction (meld score greater than 12), or kidney dysfunction (serum creatinine above the upper limit of normal); 7. patients with severe psychiatric illness. 8. pregnant or lactating women. 9. patients who have a history of taking hormonal drugs. 10. diabetic patients whose blood sugar cannot be controlled to be within 6.1 - 8.3 mmol/l. 11. patients with other clinical and laboratory conditions that are considered by researchers as inappropriate for participating in this trial. exit criteria 1. patients with other non-tumor diseases that prevent them from continuing to receive this treatment regimen. 2. patients who need emergency surgical resection due to intestinal obstruction, intestinal perforation, intestinal bleeding, etc. after being enrolled in the study. 3. patients with distant metastasis confirmed by intraoperative exploration or postoperative pathology, including liver, pelvic cavity, ovary, peritoneum, distant lymph node metastasis, etc. 4. patients who need combined organ resection as determined by intraoperative exploration. 5. patients who request to withdraw from this study cohort for various reasons after being enrolled in the study, or who cannot complete the study plan and follow-up for various reasons.

Keywords: total laparoscopic laparoscopic assisted intracorporeal anastomosis extracorporeal anastomosis
efficacy of autologous fibrin glue in pterygium

Conditions: Pterygium

Summary: pterygium is wing-shaped, vascular, fleshy growth that originates on the conjuntiva and that can spread to the corneal limbus and beyond the surgical exeresis with autologous conjunctival autograft technique is the treatment of choice. commercially available fibrin glue has been used preferentially for graft fixation due to its benefits compared to sutures; however, its cost and the risk of inflammatory immune reaction limit the its use. there are few studies about autologous fibrin glue. objective: to determine the efficacy of autologous fibrin glue preparation in patients undergoing pterygium resection surgery. to compare with autologous conjunctival graft fixation with suture. this is a randomized clinical trial. two patient groups will undergo pterygium excision surgery. group 1 will have autologous conjunctival graft fixation with autologous fibrin glue and group 2 will have suture graft fixation using 10.0 mononylon. early and late postoperative surgical results as well as complication rates will be analyzed.


Eligibility criteria:
inclusion criteria: * nasal primary pterygium exclusion criteria: * relapsed pterygium * patients with a history of previous eye surgery * patients with glaucoma using hypotensive eye drops * eye surface diseases * eye allergy * diabetic patients,
home-based psychoeducation for older adults with frailty: a feasibility trial

Conditions: Frailty; Well-Being, Psychological

Summary: this study aims to test the feasibility and acceptability of home-based psychoeducation in older adults with frailty in the community. the main questions it aims to answer are 1. are the proposed eligibility criteria for participants and the study process in recruiting and retaining the participants appropriate? 2. is home-based psychoeducation feasible and acceptable for older adults with frailty in the community? participants will receive 12 weekly online group-based sessions at their homes. the content for the experimental group and control group is different: * intervention group: psychoeducation * control group: physical health education participants will receive two home visits for data collection. an individual interview will be conducted with participants in the experimental group to explore their experiences.


Eligibility criteria:
inclusion criteria: (1) aged 65 years or over; (2) meeting frailty criteria by frail scale (score 3 or above) ; (3) mentally competent screened by the abbreviated mental test (amt≥6) ; (4) able to speak and understand cantonese; (5) living at home; (6) having experience using a smartphone (e.g.: sending messages, watching videos) exclusion criteria: (1) have a visual or hearing problem or a language barrier that may affect their communication or understanding; (2) being unfit for home-based exercise, as defined by having one point or above at either the 25-item home falls and accidents self-reported screening tool (home-fast), which is a comprehensive tool for identify home hazards for fall (3) are currently practising exercise for at least 150 minutes per week in previous four weeks; (4) are receiving active psychiatric or antidepressant treatment or joining other physical exercises or rehabilitation programmes

Keywords: subjective well-being frailty psychoeducation
pharmacokinetics of liposomal amphotericin b in critically ill vs. non-critically ill hematological patients: exploration of covariates

Conditions: Pharmacokinetics; Liposomal Amphotericin B; Critically Ill Patients

Summary: this prospective study will compare the pharmacokinetic exposure to liposomal amphotericin b between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.

this phase iv, open label, non-randomized, monocenter pharmacokinetic study will be carried out in critically ill and non-critically ill (hematology) patients receiving multiple dose treatment with l-amb. the pharmacokinetic exposure to liposomal amphotericin b in plasma, urine, bal and ascitic fluid will be compared between the two population groups in an early and late exposure day. correlating covariates will be identified to provide a rationale for optimal dosing strategy in critically ill patients.

Eligibility criteria:
inclusion criteria: * treatment with l-amb * admitted to an icu or hematology ward exclusion criteria: * dnr 2 or 3 * pregnant or lactating women * previous documentation of intolerance/sensitivity to l-amb
assessment of bimodal contribution in adult cochlear implant users

Conditions: Deafness

Summary: to evaluate the combination of electric hearing through cochlear implant and acoustic hearing through hearing aid in bimodal users with moderate-to-severe hearing loss in the non-implanted ear. the research will also provide pilot study data on unilateral cochlear implant recipients with residual useful acoustic hearing in the implanted ear whose acoustic hearing has been preserved.

many current unilateral cochlear implant users have some residual acoustic hearing in the opposite ear as well as in the implanted ear. the amount of useful residual acoustic hearing varies among these implantees. there are several acoustic and electric combinations in the bilateral-bimodal listening mode depending on the amount of useful residual acoustic hearing in each ear. the combination of low frequency acoustic information provided by the hearing aid on each ear, completes the high frequency electric information provided by the cochlear implant (complementary bimodal benefit). each of the different rehabilitation combinationsfor unilateral cochlear implant users enablesa unique integration of the three aspects of bilateral hearing bilaterality, binaurality and bimodality which may provide significant advantages over unilateral cochlear implant stimulation in terms of speech perception in noise, complementary information as well as localization abilities. the study will include 20 bilateral-bimodal users with moderate-to-severe hearing loss at 250 hz, 500 hz and 1000 hz in the non-implanted ear, who use hearing aids for at least 75% of their waking hours. evaluation utilizes bilateral-binaural and bimodal complementary effects task-specific test batteries based on published doctoral research project. the assessment protocol consisted of tests that include various speech materials, different maskers, presentation of the noise from different locations in space, right/left speech lateralization, pitch-related tasks and subjective questionnaires. all tests will be administered in three listening conditions: cochlear implant -alone, hearing aid-alone and cochlear implant +hearing aid.

Eligibility criteria:
inclusion criteria: * bilateral-bimodal users * with moderate-to-severe hearing loss at 250 hz, 500 hz and 1000 hz in the non-implanted ear * who use hearing aids for at least 75% of their waking hours exclusion criteria: -

Keywords: bimodal cochlear implant hearing aid auditory perception